Using Equivalent Income Concept in Blood Pressure Lowering Drugs Assessment. How Include Inequality Aversion in Cost/Benefit Analysis?

Anne-Laure Samson (1) , Clémence Thebaut (2) , Brigitte Dormont (2) , Marc Fleurbaey (3) , Stéphane Luchini (4) , Erik Schokkaert (5) , Carine van de Voorde (5)

1 LEDa - Laboratoire d'Economie de Dauphine
2 LEDa - Laboratoire d'Economie de Dauphine
3 Woodrow Wilson School and Center for Human Values
4 GREQAM - Groupement de Recherche en Économie Quantitative d'Aix-Marseille
5 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven

Health equivalent income concept [...]

Mots clés: Cost/Benefit Analysis

Domaines: Économie et finance quantitative [q-fin]; Santé publique et épidémiologie

Anne-Laure Samson, Clémence Thebaut, Brigitte Dormont, Marc Fleurbaey, Stéphane Luchini, et al.. Using Equivalent Income Concept in Blood Pressure Lowering Drugs Assessment. How Include Inequality Aversion in Cost/Benefit Analysis?. Health Technology Assessment international annual meeting (HTAi 2014), Jun 2014, Washington, DC, United States. ⟨hal-01475275⟩